On Friday,
Medigus Ltd. (NASDAQ: MDGS, Forum) reported that one of its subsidiaries,
Polyrizon Ltd., had engaged with a full-service Contract Research Organisation, to advise the company in its pursuit of Food and Drug Administration (FDA) submission for its products.
Medigus owns 37.01% of the clinical development biotech company and that company intends to start working on a readiness plan for its preventative products for SARS-CoV-2, coronavirus, influenza and allergens, in order to prepare for US FDA submission.
For full details on this news, click
here.
In recent pre-clinical studies, Polyrizon products demonstrated their potential in capturing and containing human coronavirus 229E and H1N1 influenza from interacting with epithelial host cells and by inhibiting cell death. Polyrizon’s proprietary Capture and Contain hydrogel platform is delivered in the form of nasal sprays and forms a thin gel-based protective shield containment barrier in the nasal cavity.
In September, Polyrizon announced that it had submitted a patent application for its products preventing of pathogens such as coronavirus and allergens from affecting nasal tissue.
Generally pertaining to the field of hydrogels that are capable to capture and contain biological assaults intrusion through the upper airways and eye cavities, that invention details a novel modality for a delivery system for drugs through the nasal mucosa that could get more drug into the body and resides longer in the nasal cavity.
Polyrizon’s product candidate protects the nasal cavity and the respiratory tract. In its H1N1 studies, product candidates demonstrated high efficacy by preventing the influenza virus from affecting epithelial host cells and inhibit cells death.
It was also pointed out that use of the
Capture and Contain platform technology would help provide a boost in Polyrizon’s product line extended against flu and cold viruses along with a variety of different respiratory viruses.
Medigus is a technology company that works with advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions.
For more details on the company, visit
medigus.com.
FULL DISCLOSURE: Medigus Ltd. Is a client of Stockhouse Publishing.